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Abstract
Background—In 2015, only 42% of Puerto Rican (PR) girls aged 13–17 and 44% of U.S. 
Hispanic girls aged 13–17 were vaccinated with all three Human Papillomavirus (HPV) vaccine 
doses; These percentages were far lower than the Healthy People 2020 goal of 80% of girls aged 
13–15 the Healthy People 2020 goal of 80%. The purpose of this study was to examine potential 
differences in HPV awareness and knowledge and HPV vaccine awareness and acceptability 
between a population-based sample of U.S. Hispanic and island Puerto Rican women.
Methods—We restricted our analyses to female respondents from the Health Information 
National Trends Survey (HINTS) 2007 (n=375; U.S. Hispanic) and HINTS Puerto Rico 2009 
(n=417; PR). Using the Wald chi-square test, we assessed if there were significant differences in 
HPV awareness and knowledge and HPV vaccine awareness and acceptability between U.S. 
Hispanic and island PR women. We then utilized logistic or multinomial regression to control for 
covariates on significant outcomes.
Results—Both groups of Hispanic women were highly knowledgeable that HPV causes cancer 
(89.2% in both samples) and that HPV is a sexually transmitted infection (78.1% [U.S. Hispanics] 
and 84.7% [PR]). Less than 10% of both groups recognized that HPV can clear on its own without 
treatment. Island PR women had significantly higher HPV vaccine awareness (66.9% vs. 61.0%; 
Wald X2 F(1, 97) = 16.03, p < .001) and were more accepting of the HPV vaccine for a real or 
hypothetical daughter, compared to U.S. Hispanic women (74.8% vs. 56.1%; Wald X2 F(2, 96) = 
7.18, p < .001). However, after controlling for sociodemographic variables and survey group, there 
was no longer a difference between the two groups of women and HPV vaccine awareness (AOR 
= .53; 95% CI = .23, 1.24). Moreover, after controlled analysis, island PR women were 
significantly less likely to have their hypothetical daughter get the HPV vaccine, compared to U.S. 
Hispanic women (AOR = 0.26; 95% CI = .08, .81).
Conclusions—Future research focused on factors contributing to differences and similarities in 
HPV knowledge and awareness and HPV vaccine awareness and acceptability between these two 
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groups of Hispanic women is warranted. Findings may assist in developing health education 
programs and media to promote HPV vaccination among both groups.
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INTRODUCTION
Cancer is the leading cause of death among Hispanics in the United States (U.S.) (American 
Cancer Society, 2012), and the second leading cause of mortality in Puerto Rico (PR) 
(Figueroa-Vallés et al., 2012). Data from the National Cancer Institute (NCI) indicate that 
U.S. Hispanic women have higher 5-year (2009–2013) cervical cancer incidence (9.4 vs. 
7.5/100,000) and mortality (2.6 vs. 2.3/100,000) rates than non-Hispanic white women 
(Howlader et al., 2014), signifying apparent health disparities between these two population 
groups. PR Central Cancer Registry 2006–2010 data indicate that Puerto Rican women have 
similar disparities in cervical cancer incidence (11.8 vs. 9.9) and mortality (2.6 vs. 2.7) when 
compared to U.S. Hispanic women (Figueroa-Vallés, et al., 2012). Prevention of cervical 
cancer is possible through the use of three vaccines (i.e., Cervarix [bivalent], Gardasil 4 
[quadrivalent], and Gardasil 9 [nonavalent]), which protect against the oncogenic strains of 
human papillomavirus (HPV) that cause the majority of all HPV-related cancer cases, 
including cervical cancer (Petrosky, et al., 2015). HPV vaccination is recommended for 
females aged 9–26 and males aged 9–21, though most vaccination efforts primarily focus on 
11- and 12- year-old adolescents (Petrosky et al., 2015). Currently, the U.S. Vaccines for 
Children (VFC) program (Centers for Disease Control and Prevention, 2012) provides 
vaccination for children who are low-income and uninsured. Provisions of the Affordable 
Care Act (U.S. Department of Health and Human Services, 2014), as well as PR state law 
(Ortiz et al., 2012), also require health insurers to cover the HPV vaccine for girls aged 11–
18 years. However, despite clinical guidance and widespread availability of the vaccine, not 
all Hispanic girls in the U.S. and PR receive this cancer prevention vaccine. Two-thirds of 
(66%) U.S. Hispanic girls received ≥1 dose of the vaccine in 2015 (Centers for Disease 
Control and Prevention, 2015a), and even fewer received all three doses (44%) (Centers for 
Disease Control and Prevention, 2015b). In 2015, only about three out every four (77%) 
Puerto Rican girls received ≥1 dose of the vaccine; fewer completed the HPV vaccine series 
(42%) (Reagan-Steiner et al., 2015). For both groups of females, figures fall short of the 
Healthy People 2020 target of 80% of girls aged 13–15 completing the vaccine series (U.S. 
Department of Health and Human Services, 2010).
Gaps in the literature include limited assessment of HPV vaccine acceptability and uptake 
(Bair, Mays, Sturm, Perkins, et al., 2008; Constantine & Jerman, 2007; Kepka, Ulrich, & 
Coronado, 2012; Lazcano-Ponce et al., 2001; Watts et al., 2009; Yeganeh, Curtis, & Kuo, 
2010) among underserved, low income populations such as Hispanics (Fernandez, Allen, 
Mistry, & Kahn, 2010; Kobetz et al., 2010). However, those studies that are available suggest 
that underserved Hispanic populations have limited and sometimes inaccurate levels of HPV 
knowledge, especially about the virus’ relationship to cervical cancer (Kobetz, et al., 2010; 
Morales-Campos, Markham, Peskin, & Fernandez, 2013; Tiro, Meissner, Kobrin, & 
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Chollette, 2007; Vanslyke et al., 2008). Health promotion theories (Becker, 1974; Janz & 
Becker, 1984) substantiate that HPV and HPV vaccine knowledge contribute to the adoption 
and/or maintenance of HPV vaccination. In addition, a systematic literature review focusing 
on barriers to HPV vaccination among U.S. adolescents identified a lack of knowledge 
regarding HPV and HPV vaccine as a key barrier for underserved parents (Holman et al., 
2014).
There is also a paucity of research examining differences in HPV knowledge and vaccine 
acceptability regarding adolescents within ethnic groups, such as differences between U.S. 
Hispanics and geographically-isolated island Puerto Rican Hispanics. Researchers have 
compared U.S. Hispanic, non-Hispanic Whites, non-Hispanic blacks, and island Puerto 
Ricans using population-based health data to compare disparities across racial/ethnic groups 
for breast, stomach, liver, cervical, endometrial, colorectal, and oropharyngeal cancers 
(Ortiz, Perez, et al., 2010; Ortiz, Soto-Salgado, Calo, Nogueras, et al., 2010; Ortiz, Soto-
Salgado, Calo, Tortolero-Luna, et al., 2010; Soto-Salgado et al., 2009; Suarez et al., 2009). 
Investigating if differences exist within the Hispanic ethnic group is important because it 
comprises subgroups (e.g., Mexicans, Puerto Ricans, Cubans) that have distinct cultures, 
immigration histories, healthcare experiences, and relationships to mainland U.S. In 
addition, researchers have found differences between Hispanic subgroups regarding health 
outcomes such as diabetes prevalence (Arroyo-Johnson et al., 2016), AIDS knowledge 
(Hajat, Lucas, & Kington, 2000), self-assessed health status (Hajat, Lucas, & Kington, 
2000), and interval since last physician contact (Hajat, Lucas, & Kington, 2000). 
Researchers may limit their ability to understand health disparities affecting Hispanics, 
along with their ability to appropriately target intervention efforts, by grouping all subgroups 
into a single Hispanic ethnic category for research purposes. Thus, it remains unclear if 
current explanatory models of HPV knowledge and vaccine acceptability explain behavior 
among U.S. Hispanics and geographically-isolated island Puerto Ricans, two populations 
disproportionately affected by cervical cancer and not meeting current public health HPV 
vaccination goals.
The literature also suggests adults (parents) are crucial to the success of HPV vaccine uptake 
efforts because (1) they are the primary decision-makers in their child(ren)’s medical care 
and (2) their beliefs about HPV impact HPV-related health behaviors and outcomes for their 
children. The literature indicates parents are more likely to report willingness to vaccinate if 
they: (1) feel their child is susceptible to HPV or cervical cancer (Dempsey, Zimet, Davis, & 
Koutsky, 2006; Fazekas, Brewer, & Smith, 2008; Gerend, Lee, & Shepherd, 2007; Kahn et 
al., 2009); (2) believe the vaccine is effective and provides benefits (Bair et al., 2008; de 
Visser & McDonnell, 2008; Dempsey, et al., 2006; Fazekas, et al., 2008; Gerend, et al., 
2007; Zimet et al., 2005); and (3) perceive few barriers to accessing the vaccine (Fazekas, et 
al., 2008; Sauvageau, Duval, Gilca, Lavoie, & Ouakki, 2007). The literature also provides 
mixed results (Bair, Mays, Sturm, Perkins, et al., 2008; Dempsey, et al., 2006; Fazekas, et 
al., 2008; Kahn, et al., 2009; Marlow, Waller, & Wardle, 2007; Zimet, et al., 2005) regarding 
perceptions of severity of HPV-related diseases and parental attitudes regarding vaccination. 
Approval from significant others (i.e., spouse, doctor) or a parent’s perception that 
vaccination is the norm are associated with vaccine acceptability (Dempsey, et al., 2006; 
Dinh et al., 2007; Kahn, et al., 2009; Ogilvie et al., 2007). Mothers’ compliance with Pap 
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test screening guidelines has also been positively associated with daughters’ HPV vaccine 
initiation and completion (Chao, Slezak, Coleman, & Jacobsen, 2009; Monnat & 
Wallington, 2013; Rahman, Elam, Balat, & Berenson, 2013).
Therefore, the purpose of this study was to examine potential differences in HPV awareness 
and knowledge and HPV vaccine awareness and acceptability between a population-based 
sample of U.S. Hispanic and island Puerto Rican women. Although cervical cancer or HPV 
risk is not solely determined by knowledge and awareness, these constructs are recognized 
by health promotion theories (Becker, 1974; Janz & Becker, 1984) that substantiate HPV 
and HPV vaccine knowledge contribute to the adoption and/or maintenance of HPV 
vaccination. In addition, the authors of the current paper acknowledge that the U.S. Hispanic 
and island Puerto Rican comparison has certain limitations; however, the authors consider 
this comparison important in order to highlight racial/ethnic group disparities, stimulate 
hypothesis generation, and illustrate use of an innovative, population-based island PR health 
dataset.
METHODS
Sample
The Health Information National Trends Survey (HINTS) was developed by the NCI to 
assess cancer-related behavior (e.g., prevention, screening, and treatment) in the population 
in order to assess associations between key communication constructs and behavioral 
outcomes, and to monitor trends in the rapidly evolving health communication landscape 
(Tortolero-Luna et al., 2010). HINTS 2007 used a mixed-mode, dual-frame design for 
participant recruitment. One frame was a list-assisted, random digit dial (RDD) computer-
assisted telephone interview, wherein one adult from each household was selected for an 
interview. The second frame was a relatively comprehensive national listing of addresses 
available from the U.S. Postal Service for the purpose of administering a mail survey. Both 
the RDD and mail survey were conducted from January through April 2008. The overall 
response rates were 24.2% for the RDD household screener and 40.0% for the mailed survey 
(Cantor et al., 2007; Davis, Dipko, & Sigman, 2009).
HINTS-PR 2009 used a RDD and a computer-assisted telephone interview system. It used a 
stratified sampling frame representing eight geographic regions designated by the PR 
Department of Health. Within each stratum, sampled telephone numbers were selected with 
equal probability. Non-working and non-residential numbers were eliminated from the 
sample. Data were collected from April to June 2009. Trained bilingual Puerto Rican 
interviewers collected 639 interviews from 837 screened households. The unweighted 
screener and extended interview response rate both equaled 76.3%. Further details on the 
HINTS 2007 and HINTS-PR 2009 samples and sampling designs are published elsewhere 
(Cantor, et al., 2007; Davis, et al., 2009).
For the current study, we restricted our analyses to female respondents in both surveys for a 
total sample of 792 women (n = 375; U.S. Hispanic HINTS 2007 and n = 417; HINTS-PR 
2009). We selected only adult female respondents for the study because, at the time of 
survey implementation, the focus was on cervical cancer prevention for women and the HPV 
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vaccine was only recommended for girls. In addition, some of our outcome variable 
questions were only asked of women. Despite differences in methods of sampling and data 
collection between the HINTS 2007 and HINTS-PR 2009, the overlap in question content 
provides a point of comparison to examine potential variability in HPV awareness and 
knowledge and HPV vaccine awareness and acceptability between U.S. Hispanic and island 
Puerto Rican women. The ability to compare the samples is a strength, not only because 
island Puerto Ricans are typically not included in U.S. public health data (Calo & Ortiz, 
2015), but also because detailed data for Hispanic subgroups are lacking (Escarce, Morales, 
& Rumbaut, 2006). Due to the de-identified nature of the publicly-available HINTS data, the 
University of Texas Health Science Center at San Antonio Institutional Review Board 
deemed this secondary data analysis exempt from review.
Measures
Measures collected included: sociodemographics, Pap test screening history, health status, 
HPV awareness and knowledge, and HPV vaccine awareness and acceptability. Specifically, 
HPV awareness and knowledge, and HPV vaccine awareness and acceptability were used as 
dependent variables, and sociodemographics, Pap test screening history, and health status as 
covariates.
Sociodemographic Characteristics—Sociodemographics included: age (18–34 years, 
35–49 years, 50–64 years, 65+ years), health status (excellent/very good, good, fair/poor), 
health care coverage (yes/no), occupational status (employed, unemployed/other, 
homemaker), marital status (married/living as married, separated/divorced/widowed/single, 
never been married), education (high school graduate or less, some college or more), born in 
U.S. (yes/no), place of birth (PR, U.S. mainland, other), number of children under 18 in 
household (0/1 or more), female children in household (yes/no), and annual household 
income (less than $35,000/$35,000 or more).
Family history of cancer—Respondents were asked, “Have any of your family members 
ever had cancer?” Response options were: yes, no, and has no family.
Pap test screening history—Respondents were asked, “When did you have your most 
recent Pap test?” Response options were: a year ago or less, more than 1 but not more than 3 
years ago, more than 3 but not more than 5 years before, and more than 5 years ago.
HPV and HPV vaccine awareness—Participants were asked, “Have you ever heard of 
HPV? HPV stands for Human Papillomavirus. It is not HIV, HSV or herpes.” and “Have you 
heard anything about a vaccine or shot to prevent cervical cancer?” Response options for 
both questions were: yes, no, and don’t know.
HPV knowledge—Only women who responded “yes” to having heard of HPV were asked 
three HPV knowledge questions. The questions assessed whether a woman could correctly 
identify that HPV (1) causes cervical cancer, (2) is transmitted through sexual contact, and 
(3) may go away on its own without treatment. Response options were yes or no.
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HPV vaccine acceptability—A description of the HPV vaccine was read to respondents: 
“A vaccine to prevent the human papillomavirus or HPV infection is recommended for girls 
ages 11–12 and is called the cervical cancer vaccine, HPV shot, or GARDASIL®.” To 
assess vaccine acceptability, respondents were asked: “If you had a daughter that age, would 
you have her get it?” Response options were: yes, no, not sure/it depends, and don’t know.
Analytic Approach
We used STATA 12.0 for all analyses (StataCorp, 2009). Because of the HINTS sample 
design and weighting procedures, we used the jackknife variance estimation technique. For 
the purposes of these analyses, we coded “don’t know” responses as equivalent to “missing” 
because of data patterns where some categories had no data, otherwise known as quasi-
complete separation, causing convergence failures in logistic regression models (Allison, 
2008). Missing data were excluded from the analyses. We used descriptive statistics (e.g., 
overall sample size, sample sizes in important subgroups, and the proportion of subjects in 
each of the sociodemographic categories) to describe the sample and the distribution of 
variables. To assess if there were significant difference between U.S. Hispanics and island 
PR women, we conducted the Wald chi-square test. We selected the Wald X2 test because 
(1) all our variables are categorical and our research question was to look at difference 
between two groups (U.S. Hispanic women and island PR women) and (2) our dataset is 
population-based. In addition, for any significant outcomes from the Wald X2 test, we 
conducted logistic or multinomial regression to adjust for covariates. Because we performed 
multiple tests on our data, we utilized the modified Bonferroni procedure to control for type 
1 error (Holland & Copenhaver, 1988).
RESULTS
Sample Sociodemographics
Table 1 presents sociodemographic information for both study samples. U.S. Hispanic 
women were commonly between the ages of 35–49 (31.5%), born in the U.S. (53.1%), 
employed (47.7%), married/living as married (56.3%), and in excellent/very good health 
(36.1%), with a high school education or less (53.8%). U.S. Hispanic women also had high 
rates of health insurance coverage (70.8%), were likely to have one or more children in the 
household (54.7% of these, 59.5% had female children), and commonly reported an annual 
income less than $35,000 (54.1%). Almost two in five island PR women were aged 65 or 
older (39.1%) and a high school education or less (51.9%); the majority were born in PR 
(95.2%). Less than half of island PR women were homemakers (43.4%), married/common 
law (48.0%), and in fair/poor health (40.3%). Although four out of five PR women reported 
an annual income of less than $35,000 (82.6%), they were well covered by health insurance 
(96.2%). Approximately, one-quarter of these women had one or more children in the 
household (26.4%); of these women, 65.5% had female children. The majority of both 
groups of Hispanic women were up to date on their Pap test screening (88.7% and 81.1%, 
respectively) using current screening guidelines (U.S. Preventive Services Task Force, 
2012).
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Bivariate Analysis
Table 2 depicts the proportion of the two samples that had ever heard of HPV and the HPV 
vaccine. Both samples had moderately high awareness of HPV (64.0% [U.S. Hispanics] vs. 
65.5% [PR]). Similarly, both groups of women were highly knowledgeable that HPV causes 
cancer (89.2% in both samples) and that HPV is a sexually transmitted infection (78.1% 
[U.S. Hispanics] and 84.7% [PR]). Less than 10% of both groups recognized that HPV can 
clear on its own without treatment. Island PR women had significantly higher HPV vaccine 
awareness (66.9% vs. 61.0%; Wald X2 F(1, 97) = 16.03, p < .001) and were more accepting 
of the HPV vaccine for a real or hypothetical daughter (74.8% vs. 56.1%; Wald X2 F(2, 96) 
= 7.18, p < .001), compared to U.S. Hispanic women. Of those women who had a female 
child in the home, 56.3% of U.S. Hispanic women indicated acceptance of the HPV vaccine, 
compared to 76.4 % of island PR women (Wald X2 F(2,96) = 3.70, p < .03). For HPV 
vaccine awareness and acceptability, we conducted additional analyses to further explore the 
significant findings.
Regression Analysis
As shown in Table 3, results from the adjusted logistic regression model indicate that after 
controlling for age, health insurance, occupational status, education, number of children in 
household, annual income, family history of cancer, and survey group, there was no longer a 
significant difference between the two groups of Hispanic women and HPV vaccine 
awareness (AOR = .53; 95% CI = .23, 1.24; p = .14). Women having at least some college 
education were also 52% less likely to report being aware of the HPV vaccine compared to 
women having a high school education or less (AOR = .48; 95% CI = .25, .91; p = .03).
Regarding HPV vaccine acceptability, results from the adjusted multinomial regression 
model comparing revealed that island PR women were significantly less likely to have their 
hypothetical daughter get the HPV vaccine, compared to US Hispanic women (AOR = 0.26; 
95% CI = .08, .81; p=.02). Within the total sample, none of the sociodemographic variables 
were statistically associated with HPV vaccine acceptability (Table 4).
DISCUSSION
To our knowledge, this is the first study to examine potential differences in HPV awareness 
and knowledge and HPV vaccine awareness and acceptability between a population-based 
sample of U.S. Hispanic and island PR women. The majority of U.S. Hispanic women and 
island PR women in this study reported high levels of HPV awareness. Some studies have 
reported similar results (Allen et al., 2010; Kepka, et al., 2012; Morales-Campos, et al., 
2013), while others have reported low levels of HPV awareness among Hispanics (Bair, 
Mays, Sturm, & Zimet, 2008; Vanslyke, et al., 2008). This inconsistency may be attributed 
to some of the studies having been conducted prior to the HPV vaccine’s licensure and prior 
to media advertising campaigns bringing attention to HPV and preventive vaccination. 
Among the women who had heard of HPV in our study, knowledge levels were high. The 
majority of women in both Hispanic samples correctly identified that HPV causes cancer, is 
transmitted through sexual contact, and can clear on its own. Kobetz et al. (2010) reported 
similar findings among U.S. Hispanic women, while other studies of Hispanic women 
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reported low levels of HPV knowledge (Kepka, et al., 2012; Vanslyke, et al., 2008). 
Fernandez et al.’s (2014) study of PR women also found low levels of HPV and cervical 
cancer knowledge. These inconsistencies in both U.S. Hispanic and PR samples could be 
due to variations in how researchers measured HPV knowledge and in the different samples 
of Hispanic women who participated in these studies.
In bivariate analyses, our study found that island PR women were more aware of and 
accepting of the HPV vaccine when compared to U.S. Hispanic women, but the literature 
shows inconsistencies. Colon-Lopez et al. (2015) found similar findings in their sample of 
parents attending a federally qualified health center in PR. In that particular study, over half 
of the parents had heard of the HPV vaccine and more than three-quarters were willing to 
get their child vaccinated. Conversely, Fernandez et al. (2014), in their study of mothers and 
daughters living in PR, found that there was low knowledge of HPV vaccination; mothers 
also reported reluctance to vaccinate their daughters due to concerns about vaccine efficacy 
and benefits of HPV vaccination. Our findings could also be attributed to when the data 
(2008 vs. 2009) for each sample were collected. In 2008, the HPV vaccine had only been 
licensed for use for two years, compared to three years with the PR sample. Thus, the island 
PR survey respondents may have received more exposure to HPV vaccine media advertising 
and/or recommendations from health care providers. Interestingly, when controlling for 
significant sociodemographics and survey group, significant differences in HPV vaccine 
awareness and acceptability were no longer present between the two groups of women. This 
shift illustrates the important influence of social determinants of health (e.g., education), on 
awareness of and action on preventive health measures.
Limitations
The limitations of this study include its cross-sectional study design, overall low survey 
response rate, differing years of data collection, and small sample size for both U.S. 
Hispanic (HINTS 2007; n = 375) and island PR (HINTS-PR 2009; n = 417) women. The 
current study provides a snapshot of U.S. Hispanic and island PR women at one point in 
time; thus, we are unable to draw any conclusions about causal relationships between 
awareness, knowledge, and vaccine acceptability. HINTS 2007 response rates were low, 
which could raise issues regarding selection bias for those who did versus did not respond, 
especially in underserved populations. HINTS 2007 and HINTS-PR 2009 data were 
collected seven to ten years ago; given the time that has passed, the HPV vaccination 
environment has changed over the years, potentially altering the methods of information 
dissemination. The HINTS 2007 survey also did not collect information from respondents 
regarding country of origin; thus, we were unable to differentiate the sample into cultural 
groups (e.g., Mexican, Cuban, Puerto Rican). We acknowledge that although island PR are a 
Hispanic subgroup, U.S. Hispanics comprise individuals from different Hispanic subgroup 
origins, each of which may have variable beliefs, attitudes, knowledge, and cervical cancer 
incidence and mortality rates (Pinheiro et al., 2009). Although comparing U.S. Hispanics to 
island PR is not a perfect comparison, racial/ethnic groups may identify differences in 
personal determinants of health that could potentially impact HPV-related cancer prevention 
efforts in vulnerable populations and generate hypotheses about how these determinants and 
other environmental factors impact uptake of the HPV vaccine. The findings provide 
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evidence that similarities and differences in HPV knowledge and awareness and HPV 
vaccine awareness and acceptability do exist between ethnic subgroups that otherwise are 
routinely excluded from or grouped together in public health research. Furthermore, this 
current analysis extends the original intent of HINTS-PR, which was to use the collected 
data for secondary data analyses, including regional geographic comparisons within PR and 
comparison of differences between HINTS-PR and mainland HINTS results, and to inform 
cancer control research and practice for Hispanic populations (Tortolero-Luna et al., 2010).
CONCLUSION
Given that both U.S. Hispanic and island PR women have higher cervical cancer incidence 
and mortality rates than non-Hispanic white women, our findings provide novel insight into 
similarities and differences between groups regarding HPV awareness and knowledge and 
HPV vaccine awareness acceptance that may assist in developing culturally appropriate 
health promotion programs to improve HPV vaccination rates among both groups. Future 
research should further explore these in-group differences, especially reasons why island PR 
women may be more accepting of the HPV vaccine overall, but also why differences may 
exist within specific PR sociodemographic groups. Further qualitative and quantitative 
assessments of what in the PR socio-cultural context or environment influences acceptance 
(or non-acceptance) of the HPV vaccine may contribute to the current body of evidence and 
aid in the development of effective health education programs.
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Table 1
Demographics of U.S. Hispanic women (n=375; HINTS 2007) and island Puerto Rican (PR) women (n=417; 
HINTS-PR 2009), N = 792.
U.S. Hispanic
n (%)
Island PR
n (%) p-value
4
(Wald X2)
Pap test screening history 1 year ago or less 230 (66.9) 232 (61.1) 0.58
More than 1 but not more than 3 years ago 75 (21.8) 76 (20.0)
More than 3 but not more than 5 years ago 14 (4.1) 29 (7.6)
More than 5 years ago 24 (7.0) 43 (11.3)
Family history of cancer2 Yes 216 (58.7) 277 (66.8) .03
No 152 (41.3) 138 (33.3)
Health Status Excellent/Very Good 135 (36.1) 99 (23.7) .05
Good 133 (35.6) 150 (36.0)
Fair/Poor 106 (28.3) 168 (40.3)
Age2 18–34 112 (29.9) 42 (10.1) <.001
35–49 118 (31.5) 81 (19.4)
50–64 90 (24.0) 128 (30.7)
+65 55 (14.6) 163 (39.1)
Health Insurance2 Yes 264 (70.8) 401 (96.2) <.001
No 109 (29.2) 16 (3.8)
Occupational Status2 Employed 178 (47.7) 100 (24.0) <.001
Unemployed/Other 113 (30.4) 136 (32.6)
Homemaker 81 (21.7) 181 (43.4)
Marital Status Married/Living as married 211 (56.3) 200 (48.0) .14
Separated/Divorced/Widowed/Single (never married) 164 (43.8) 217 (52.1)
Education2 High school or less 201 (53.8) 215 (51.9) .02
Some college or more 173 (46.2) 200 (48.2)
Born in U.S.1 Born in U.S. 205 (53.1) 9 (2.2) NA
Other/Puerto Rico 181 (46.3) 397 (97.8)
No. of children under 18 in household2 0 169 (45.3) 307 (73.6) <.001
1 or more 204 (54.7) 110 (26.4)
Female children in household3 Yes 122 (59.5) 72 (65.5) 0.43
No 83 (40.5) 38 (34.6)
Annual Income2 Less than $35,000 185 (54.1) 206 (82.6) <.001
$35,000 or more 157 (46.0) 43 (17.2)
Note:
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1
HINTS 2007 participants were asked were you born in the U.S., with response options Yes or No, whereas HINTS-PR 2009 participants were 
asked where were you born, with response options Puerto Rico, continental U.S., or other.
2Variable has missing data.
3
n=170 U.S. Hispanic and n=307 island PR skipped this question due to HINTS survey skip pattern.
4p-value = significant at .05 level.
NA = Not Applicable.
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Table 2
Differences in HPV awareness, HPV vaccine awareness, HPV knowledge, and HPV vaccine acceptability 
between U.S. Hispanic women (n=375; HINTS 2007) and island Puerto Rican (PR) women (n=417; HINTS-
PR 2009), N = 792.
U.S.
Hispanic
n (%)
Island PR
n (%) p-value
3
(Wald X2)
HPV Awareness2 Yes 236 (64.0) 271 (65.5) 0.15
No 133 (36.0) 143 (34.5)
HPV Vaccine Awareness2 Yes 224 (61.0) 279 (66.9) <.001
No* 143 (39.0) 138 (33.1)
HPV Knowledge1 HPV causes cancer2 0.91
  Yes 181 (89.2) 189 (89.2)
  No 22 (10.8) 23 (10.9)
HPV is transmitted through sexual contact2 .041
  Yes 164 (78.1) 183 (84.7)
  No 46 (21.9) 33 (15.3)
HPV goes away on its own2 0.17
  Yes 18 (8.3) 14 (5.8)
  No 199 (91.7) 227 (94.2)
HPV Vaccine Acceptability2 Yes 205 (56.1) 312 (74.8) <.001
No 81 (22.2) 27 (6.5)
Not Sure 79 (21.6) 68 (16.3)
Note:
1
Participants who answered “No” to the HPV awareness question (n=281) skipped all the subsequent HPV knowledge questions due to HINTS 
survey skip pattern.
2Variable has missing data.
3p-value = significant at .05 level.
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